Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) ...

The late-stage readout suggests that HRS9531 can hold its own against Eli Lilly’s blockbuster GLP-1/GIP agonist Zepbound, ...

The molecule, developed in collaboration with Massachusetts-based Kailera Therapeutics, is headed for a new drug application ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Ideaya Biosciences (IDYA) and Jiangsu Hengrui Pharmaceuticals Co. announced the publication of an abstract for an oral presentation on IDE849 at ...

The results position Hengrui to seek approval of the Zepbound-like drug in China, and Kailera, a well-funded startup, to ...

U.S.-based Kailera Therapeutics and Chinese firm Jiangsu Hengrui Pharmaceuticals' experimental weight-loss drug has helped overweight patients lose up to 17.7% of body weight in a late-stage study in ...

Hengrui Pharma delivered a strong international presence, featuring 15 innovative drugs and 72 research outcomes. These included 4 oral presentations, 5 rapid oral presentations, 27 poster ...

Hengrui also has drugs in Phase I clinical trials in the U.S. “I wouldn’t say that our lab is more productive than a lab operated by a multinational drug firm,” Tao says.

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have reported positive topline data from Hengrui’s Phase II obesity trial, considering an 8mg dose of the companies’ GLP-1/GIP receptor ...

Jiangsu Hengrui Pharmaceuticals Co. has started taking investor orders for a Hong Kong listing that could raise as much as HK$9.9 billion ($1.3 billion), the latest significant deal to boost the ...

Hengrui and Incyte will assume all financial obligations associated with the development and commercialization of SHR-1210 in their respective territories, Incyte said. “We are pleased to see ...